Goodwin’s Life Sciences and Intellectual Property teams won four awards, and were shortlisted in eleven additional categories at the 2018 LMG Life Sciences Awards hosted in New York City on September 12. The awards recognized and honored the leading lawyers, firms and in-house counsel teams who have played a significant role in the life sciences industry over the past year.
Goodwin received the following awards:
- Life Cycle Firm of the Year
- Finance & Transactional Deal of the Year (Vertex Pharmaceuticals and CRISPR Therapeutics strategic research collaboration valued at $2.1 billion)
- Patent Impact Case of the Year (GlaxoSmithKline et al v. Teva Pharmaceuticals)
- US Rising Star: Regulatory (Alexander Varond)
The firm was also shortlisted in the following eleven categories:
- Intellectual Property Firm of the Year
- Hatch-Waxman Litigation Firm of the Year: Generic
- Regulatory Firm of the Year
- Corporate Firm of the Year
- Licensing & Collaboration Firm of the Year
- Venture Capital Firm of the Year
- Regulatory Attorney of the Year: Pharmaceutical
- Corporate Attorney of the Year: Finance & Corporate (Kingsley Taft)
- Hatch-Waxman Litigator of the Year: Generic
- General Patent Litigator of the Year: New England (Elaine Blais)
- Patent Strategy & Management Attorney of the Year: Massachusetts (Duncan Greenhalgh)
LMG Life Sciences aims to present attorneys and firms in a way that speaks to the intricacies of both the legal market and the life sciences industry. The guide’s distinctive editorial structure highlights firms that specialize in four main practice areas by editorializing ranked firms and by listing our Life Sciences Stars in a way that shows overlap between certain legal areas.